Ligand Pharma (LGND) Misses Q4 EPS by 45c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.60 -1.43%
Revenue Growth %: -32.2%
Financial Fact:
Collaborative research and development and other revenues: 1.7M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -32.2%
Financial Fact:
Collaborative research and development and other revenues: 1.7M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $0.74, $0.45 worse than the analyst estimate of $1.19. Revenue for the quarter came in at $38.2 million versus the consensus estimate of $40.34 million.
GUIDANCE:
Ligand Pharma sees FY2017 EPS of $2.70.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
- Dell’s earning report was bullish for Intel CPU demand, analyst says
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
